Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder (NCT06846320)
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 as an Adjunct to Antidepressant Therapies in the Treatment of Subjects With Generalized Anxiety Disorder Who Have Had an Inadequate Response to Antidepressant Therapies
🩺 Plain-English Summary (8th-Grade Level)
Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD. The purpose of this study is to assess how safe and effective ABBV-932 is when added to the antidepressant therapies in adult participants with GAD who have had an inadequate response ADTs. ABBV-932 is an investigational drug being developed for the adjunctive treatment of GAD. Participants will be randomly assigned to receive ABBV-932 or Placebo in addition to their currently prescribed ADTs. There is 1 in 3 chance of participants assigned to Placebo. Approximately 315 adult participants with GAD and inadequate response to ADTs will be enrolled in approximately 50 sites in the United States and Puerto Rico. Participants will receive oral capsules of ABBV-932 or matching placebo in addition to their prescribed ADT for 6 weeks and then will be followed for an additional 4 week follow-up period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Who can join: Review the eligibility criteria below.
Location: University of Alabama - Huntsville Regional Medical Campus /ID# 267818 — Huntsville, Alabama
Age range: 18 Years to 65 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (52 Sites)
Showing the first 25 of 52 sites.
- University of Alabama - Huntsville Regional Medical Campus /ID# 267818 — Huntsville, Alabama
- Ima Clinical Research Phoenix (Alea) /ID# 275737 — Phoenix, Arizona
- Noble Clinical Research /ID# 267952 — Tucson, Arizona
- Advanced Research Center /ID# 267874 — Anaheim, California
- Axiom Research /ID# 267814 — Colton, California
- Sun Valley Research Center /ID# 267864 — Imperial, California
- Synergy San Diego /ID# 267879 — Lemon Grove, California
- Alliance for Research Alliance for Wellness /ID# 267911 — Long Beach, California
- NRC Research Institute DTLA /ID# 267832 — Los Angeles, California
- Excell Research /ID# 267918 — Oceanside, California
- Inland Psychiatric Medical Group /ID# 268598 — Temecula, California
- Sunwise Clinical Research /ID# 267863 — Walnut Creek, California
- Connecticut Clinical Research - Cromwell /ID# 271241 — Cromwell, Connecticut
- Cns Healthcare - Jacksonville /ID# 268588 — Jacksonville, Florida
- Accel Research Sites Network - St. Pete /ID# 267821 — Largo, Florida
- K2 Medical Research, LLC /ID# 267841 — Maitland, Florida
- GMI Florida - Central Miami Medical Institute /ID# 267839 — Miami, Florida
- Allied Biomedical Res Inst Inc /ID# 267813 — Miami, Florida
- Apg Research /ID# 271707 — Orlando, Florida
- Psych Atlanta /ID# 267878 — Marietta, Georgia
- iResearch Savannah /ID# 267865 — Savannah, Georgia
- University of Chicago Medical Center /ID# 275131 — Chicago, Illinois
- Collective Medical Research /ID# 272015 — Overland Park, Kansas
- CenExel /ID# 267853 — Gaithersburg, Maryland
- Elixia - Springfield /ID# 267815 — Springfield, Massachusetts
📞 Contact the Study Coordinator
Phone: (844) 663-3742
Email: abbvieclinicaltrials@abbvie.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Generalized Anxiety Disorder (GAD)
- Stepped Care Treatment for Anxiety Resilience — Houston, Texas
- Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder — Kingston, Ontario
- Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder — Detroit, Michigan
- Personalized AI-Driven Models in Cognitive Behavioral Therapy for Anxiety — Los Angeles, California
- Text Message Safety Behavior Fading for Pathological Worry — Tallahassee, Florida
Explore by condition: All Generalized Anxiety Disorder (GAD) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.